Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 1
1960 3
1962 1
1963 5
1964 6
1965 1
1966 5
1967 2
1968 9
1969 6
1970 2
1971 4
1972 11
1973 12
1974 9
1975 13
1976 14
1977 23
1978 13
1979 11
1980 13
1981 12
1982 11
1983 22
1984 12
1985 14
1986 18
1987 23
1988 22
1989 18
1990 25
1991 17
1992 22
1993 26
1994 38
1995 28
1996 36
1997 33
1998 39
1999 56
2000 62
2001 51
2002 48
2003 73
2004 76
2005 80
2006 86
2007 87
2008 93
2009 107
2010 119
2011 152
2012 157
2013 143
2014 141
2015 156
2016 197
2017 191
2018 197
2019 173
2020 179
2021 219
2022 204
2023 168
2024 165
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,545 results

Results by year

Filters applied: . Clear all
Page 1
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: ueno t. Immunity. 2020 Jul 14;53(1):187-203.e8. doi: 10.1016/j.immuni.2020.06.016. Epub 2020 Jul 7. Immunity. 2020. PMID: 32640259 Free article.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ueno t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: ueno t. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Nagasaki J, et al. Among authors: ueno t. Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331. Cell Rep. 2022. PMID: 35108529 Free article.
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S,… See abstract for full author list ➔ Namkoong H, et al. Among authors: ueno t. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: ueno t. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
[CHARISMA study].
Sasaki K, Ueno T. Sasaki K, et al. Among authors: ueno t. Nihon Rinsho. 2016 Jun 20;74 Suppl 4 Pt 1:715-9. Nihon Rinsho. 2016. PMID: 27534256 Japanese. No abstract available.
3,545 results